ACADIA Pharmaceuticals Inc. (ACAD) Earnings History
Annual and quarterly earnings data from 2000 to 2025
Loading earnings history...
ACAD EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ACAD Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 91.7% | 9.8% | 36.5% |
| 2024 | 91.5% | 24.1% | 23.6% |
| 2023 | 93.7% | -10.1% | -8.4% |
| 2022 | 98.0% | -43.2% | -41.8% |
| 2021 | 96.0% | -35.2% | -34.7% |
Download Data
Export ACAD earnings history in CSV or JSON format
Free sign-in required to download data
ACADIA Pharmaceuticals Inc. (ACAD) Earnings Overview
As of May 8, 2026, ACADIA Pharmaceuticals Inc. (ACAD) reported trailing twelve-month net income of $376M, reflecting +68.4% year-over-year growth. The company earned $2.18 per diluted share over the past four quarters, with a net profit margin of 36.5%.
Looking at the long-term picture, ACAD's historical earnings data spans multiple years. The company achieved its highest annual net income of $391M in fiscal 2025, representing a new all-time high.
ACADIA Pharmaceuticals Inc. maintains industry-leading profitability with a gross margin of 91.7%, operating margin of 9.8%, and net margin of 36.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), AXSM (-$188M net income, -28.7% margin), INTR ($1.32B net income, 8.8% margin), ACAD has room to improve margins relative to the peer group. Compare ACAD vs INVA →
ACAD Earnings vs Peers
Earnings metrics vs comparable public companies
ACAD Historical Earnings Data (2000–2025)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $391M | +72.7% | $105M | $2.29 | 36.5% | 9.8% |
| 2024 | $226M | +469.5% | $231M | $1.36 | 23.6% | 24.1% |
| 2023 | -$61M | +71.6% | -$73M | $-0.37 | -8.4% | -10.1% |
| 2022 | -$216M | -28.7% | -$224M | $-1.34 | -41.8% | -43.2% |
| 2021 | -$168M | +40.4% | -$170M | $-1.05 | -34.7% | -35.2% |
| 2020 | -$282M | -19.7% | -$287M | $-1.79 | -63.7% | -64.9% |
| 2019 | -$235M | +4.1% | -$247M | $-1.60 | -69.4% | -72.7% |
| 2018 | -$245M | +15.3% | -$247M | $-1.94 | -109.6% | -110.6% |
| 2017 | -$289M | -6.6% | -$292M | $-2.36 | -231.7% | -234.1% |
| 2016 | -$271M | -65.0% | -$273M | $-2.34 | -1565.9% | -1574.1% |
See ACAD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACAD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACAD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACAD — Frequently Asked Questions
Quick answers to the most common questions about buying ACAD stock.
Is ACAD growing earnings?
ACAD EPS is $2.18, with earnings growth accelerating to +68.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $376M.
What are ACAD's profit margins?
ACADIA Pharmaceuticals Inc. net margin is +36.5%, with operating margin at +9.8%. Above-average margins indicate pricing power.
How consistent are ACAD's earnings?
ACAD earnings data spans 2000-2025. The accelerating earnings trend is +68.4% YoY. Historical data enables comparison across business cycles.